89 related articles for article (PubMed ID: 24879805)
1. Re: Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.
Shah C; Berry S; Vicini FA
J Natl Cancer Inst; 2014 Jun; 106(6):dju134. PubMed ID: 24879805
[No Abstract] [Full Text] [Related]
2. Economic evaluation of proton radiation therapy in the treatment of breast cancer.
Lundkvist J; Ekman M; Ericsson SR; Isacsson U; Jönsson B; Glimelius B
Radiother Oncol; 2005 May; 75(2):179-85. PubMed ID: 15885828
[TBL] [Abstract][Full Text] [Related]
3. Examining the cost-effectiveness of radiation therapy among older women with favorable-risk breast cancer.
Sen S; Wang SY; Soulos PR; Frick KD; Long JB; Roberts KB; Yu JB; Evans SB; Chagpar AB; Gross CP
J Natl Cancer Inst; 2014 Mar; 106(3):dju008. PubMed ID: 24598714
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of radiation therapy following conservative surgery for ductal carcinoma in situ of the breast.
Suh WW; Hillner BE; Pierce LJ; Hayman JA
Int J Radiat Oncol Biol Phys; 2005 Mar; 61(4):1054-61. PubMed ID: 15752884
[TBL] [Abstract][Full Text] [Related]
5. The cost effectiveness of tamoxifen in the prevention of breast cancer.
Noe LL; Becker RV; Gradishar WJ; Gore M; Trotter JP
Am J Manag Care; 1999 Jun; 5(6 Suppl):S389-406. PubMed ID: 10538851
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer.
Delea TE; Karnon J; Smith RE; Johnston SR; Brandman J; Sung JC; Gross PE
Am J Manag Care; 2006 Jul; 12(7):374-86. PubMed ID: 16834524
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of a short stay admission programme for breast cancer surgery.
de Kok M; Dirksen CD; Kessels AG; van der Weijden T; van de Velde CJ; Roukema JA; Bell AV; van der Ent FW; von Meyenfeldt MF
Acta Oncol; 2010 Apr; 49(3):338-46. PubMed ID: 20397768
[TBL] [Abstract][Full Text] [Related]
8. Cost-effectiveness analysis of intraoperative radiation therapy for early-stage breast cancer.
Alvarado MD; Mohan AJ; Esserman LJ; Park CC; Harrison BL; Howe RJ; Thorsen C; Ozanne EM
Ann Surg Oncol; 2013 Sep; 20(9):2873-80. PubMed ID: 23812769
[TBL] [Abstract][Full Text] [Related]
9. Multimodal exercise improves quality of life of women being treated for breast cancer, but at what cost? Randomized trial with economic evaluation.
Haines TP; Sinnamon P; Wetzig NG; Lehman M; Walpole E; Pratt T; Smith A
Breast Cancer Res Treat; 2010 Nov; 124(1):163-75. PubMed ID: 20734132
[TBL] [Abstract][Full Text] [Related]
10. Effectiveness of radiation therapy for older women with early breast cancer.
Smith BD; Gross CP; Smith GL; Galusha DH; Bekelman JE; Haffty BG
J Natl Cancer Inst; 2006 May; 98(10):681-90. PubMed ID: 16705122
[TBL] [Abstract][Full Text] [Related]
11. Cost effectiveness of adjuvant trastuzumab in human epidermal growth factor receptor 2-positive breast cancer.
Liberato NL; Marchetti M; Barosi G
J Clin Oncol; 2007 Feb; 25(6):625-33. PubMed ID: 17308267
[TBL] [Abstract][Full Text] [Related]
12. Tamoxifen for breast cancer risk reduction: impact of alternative approaches to quality-of-life adjustment on cost-effectiveness analysis.
Melnikow J; Birch S; Slee C; McCarthy TJ; Helms LJ; Kuppermann M
Med Care; 2008 Sep; 46(9):946-53. PubMed ID: 18725849
[TBL] [Abstract][Full Text] [Related]
13. Effects of advanced nursing care on quality of life and cost outcomes of women diagnosed with breast cancer.
Ritz LJ; Nissen MJ; Swenson KK; Farrell JB; Sperduto PW; Sladek ML; Lally RM; Schroeder LM
Oncol Nurs Forum; 2000 Jul; 27(6):923-32. PubMed ID: 10920832
[TBL] [Abstract][Full Text] [Related]
14. [Cost effectiveness--radiation-induced telangiectasia treated with the Hyfrecator].
Rofo; 2005 Jul; 177(7):930. PubMed ID: 15973614
[No Abstract] [Full Text] [Related]
15. The promise of protons in cancer therapy.
Macready N
J Natl Cancer Inst; 2012 May; 104(9):648-9. PubMed ID: 22517986
[No Abstract] [Full Text] [Related]
16. Decision analysis of tamoxifen for the prevention of invasive breast cancer.
Grann VR; Sundararajan V; Jacobson JS; Whang W; Heitjan DF; Antman KH; Neugut AI
Cancer J; 2000; 6(3):169-78. PubMed ID: 10882333
[TBL] [Abstract][Full Text] [Related]
17. Proton therapy of cancer: potential clinical advantages and cost-effectiveness.
Lundkvist J; Ekman M; Ericsson SR; Jönsson B; Glimelius B
Acta Oncol; 2005; 44(8):850-61. PubMed ID: 16332592
[TBL] [Abstract][Full Text] [Related]
18. Assessing the potential cost-effectiveness of retesting IHC0, IHC1+, or FISH-negative early stage breast cancer patients for HER2 status.
Garrison LP; Lalla D; Brammer M; Babigumira JB; Wang B; Perez EA
Cancer; 2013 Sep; 119(17):3113-22. PubMed ID: 23775560
[TBL] [Abstract][Full Text] [Related]
19. A cost-effectiveness analysis of adjuvant trastuzumab regimens in early HER2/neu-positive breast cancer.
Kurian AW; Thompson RN; Gaw AF; Arai S; Ortiz R; Garber AM
J Clin Oncol; 2007 Feb; 25(6):634-41. PubMed ID: 17308268
[TBL] [Abstract][Full Text] [Related]
20. Effect of screening for cancer in the Nordic countries on deaths, cost and quality of life up to the year 2017.
Hristova L; Hakama M
Acta Oncol; 1997; 36 Suppl 9():1-60. PubMed ID: 9143316
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
